Digital Health Tool for Improving Medication Adherence in Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test a new text message tool designed to help Latino adults with type 2 diabetes adhere to their medication regimen. The tool sends daily messages about diet, exercise, and medication reminders, along with weekly feedback on medication-taking habits. Participants may be a good fit if they have type 2 diabetes, have struggled with regular medication adherence, and prefer receiving messages in Spanish. This tool could simplify diabetes management and reduce complications for Latino adults in the U.S. As an unphased trial, the study offers a unique opportunity to contribute to innovative solutions for diabetes management.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, since the study focuses on improving adherence to diabetes medications, it seems likely that you will continue taking them.
What prior data suggests that this digital health tool is safe for improving medication adherence in diabetes?
Research shows that the REACH-Es digital health tool, which uses text messages to assist people in taking their diabetes medication, has been well-received by adults with type 2 diabetes from various backgrounds. Studies indicate that participants responded positively to the text messages, which helped them manage their diabetes better without any major side effects. This suggests the tool is safe for people with diabetes.
The Enhanced Treatment as Usual (ETAU) approach includes standard medical care, which remains safe as it follows established medical guidelines. Adding occasional informative text messages is unlikely to cause any safety issues.
Overall, both REACH-Es and ETAU aim to help manage diabetes without introducing significant risks.12345Why are researchers excited about this trial?
Researchers are excited about these treatments because they aim to enhance medication adherence in diabetes, a critical aspect of effective disease management. Unlike traditional diabetes treatments that focus solely on medication and physician monitoring, the REACH-Es tool uniquely integrates technology by using daily SMS messages to provide personalized information and feedback on diet, exercise, and medication adherence. This includes interactive two-way messaging to engage participants actively in their care. The Enhanced Treatment as Usual (ETAU) also introduces digital elements by providing patients with updates and educational content via SMS, promoting better self-care. These innovations have the potential to improve how patients stick to their treatment plans, potentially leading to better health outcomes.
What evidence suggests that this digital health tool is effective for improving medication adherence in diabetes?
Research shows that the REACH-Es tool, which participants in this trial may receive, uses text messages to help people with diabetes take their medicines more regularly. Studies on similar text messaging tools have found that they can help people remember to take their medication more often. This is especially important for Latino individuals who face more challenges in managing diabetes. The REACH-Es system sends daily messages about diet, exercise, and medicine, along with regular updates on blood sugar levels. This approach aims to make it easier for people to manage their diabetes and reduce complications. Participants in the Enhanced Treatment As Usual (ETAU) arm will continue their usual care with additional educational messages and updates.23678
Who Is on the Research Team?
Jacqueline Seiglie
Principal Investigator
Massachusetts General Hospital
Are You a Good Fit for This Trial?
This trial is for Latino adults with type 2 diabetes who prefer to speak and read Spanish, have had suboptimal medication adherence, and an HbA1c level of ≥8.0% since 2018. Participants must be over 18, use a mobile phone with texting, and receive care at MGH-affiliated practices. Those with hearing issues or unable to handle text messages are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the REACH-Es intervention, including daily and weekly SMS related to diabetes management and adherence
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ETAU
- REACH-Es
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator